TSE:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis C$2.05 +0.13 (+6.77%) As of 07/3/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Cardiol Therapeutics Stock (TSE:CRDL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's RangeC$1.93▼C$2.0850-Day RangeC$1.47▼C$2.0552-Week RangeC$1.09▼C$3.57Volume71,011 shsAverage Volume72,622 shsMarket CapitalizationC$170.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Read More Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDL Stock News HeadlinesCardiol Therapeutics Inc. (CRDL.TO) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comStocks in play: ardiol Therapeutics Inc.April 17, 2025 | ca.finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history. | Paradigm Press (Ad)Cardiol Therapeutics reports heart failure treatment progressFebruary 21, 2025 | investing.comVernon Bernardino Issues Buy Rating on Cardiol Therapeutics Following Promising Clinical Results and Strong Financial PositionDecember 19, 2024 | markets.businessinsider.comCBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical StudyNovember 19, 2024 | benzinga.comCardiol Therapeutics added to PRISM Emerging Biotech IndexNovember 13, 2024 | markets.businessinsider.comCardiol Therapeutics Expands Trials for Heart TreatmentOctober 22, 2024 | markets.businessinsider.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at C$1.85 at the beginning of the year. Since then, CRDL shares have increased by 10.8% and is now trading at C$2.05. How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include Cardiol Therapeutics (CRTPF), Rolls-Royce Holdings plc (RR.L), Very Good Food (VRYYF), Gilead Sciences (GILD), Impel Pharmaceuticals (IMPL), Luminar Technologies (LAZR) and Meta Platforms (META). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolTSE:CRDL CIKN/A Webwww.cardiolrx.com Phone289 910 0850FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$42.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-195.07% Return on Assets-54.15% Debt Debt-to-Equity Ratio1.59 Current Ratio2.49 Quick Ratio6.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$2.11 per share Price / Cash Flow0.98 Book ValueC$0.15 per share Price / Book13.86Miscellaneous Outstanding Shares82,978,738Free FloatN/AMarket CapC$171.77 million OptionableNot Optionable Beta0.70 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (TSE:CRDL) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.